What is Asymchem Laboratories Tianjin Co Debt-to-EBITDA?
Asymchem Laboratories Tianjin CoASLTY 69 Debt-to-EBITDA is 0.22 as of Mar. 2026, which is 29% above its 10-year median of 0.17. GuruFocus rates ASLTY with a GF Score™ of 69/100 and a GF Value™ of $3.88 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 292 Biotechnology companies, Asymchem Laboratories Tianjin Co ranks better than 74.32% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Asymchem Laboratories Tianjin Co's Debt-to-EBITDA or its related term are showing as below:
ASLTY'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.17 Max: 0.47
Current: 0.23
During the past 13 years, the highest Debt-to-EBITDA Ratio of Asymchem Laboratories Tianjin Co was 0.47. The lowest was 0.03. And the median was 0.17.
ASLTY's Debt-to-EBITDA is ranked better than 74.32% of 292
companies
in the Biotechnology industry
Industry Median: 1.205
vs ASLTY: 0.23
Asymchem Laboratories Tianjin Co (OTCPK:ASLTY) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Asymchem Laboratories Tianjin Co Debt-to-EBITDA Related Terms
Asymchem Laboratories Tianjin Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co Debt-to-EBITDA Chart
ASLTY vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Asymchem Laboratories Tianjin Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asymchem Laboratories Tianjin Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Asymchem Laboratories Tianjin Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Asymchem Laboratories Tianjin Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Asymchem Laboratories Tianjin Co (ASLTY) has a Debt-to-EBITDA of 0.22 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Asymchem Laboratories Tianjin Co. This is 29% above median its historical median of 0.17. Over the past decade, Asymchem Laboratories Tianjin Co's Debt-to-EBITDA has ranged from 0.03 to 0.47. According to the industry distribution chart, Asymchem Laboratories Tianjin Co ranks #75 out of 292 companies in the Biotechnology industry, placing it in the top 25.7%.
Is Asymchem Laboratories Tianjin Co's Debt-to-EBITDA too high?
Asymchem Laboratories Tianjin Co's current Debt-to-EBITDA of 0.22 is 29% above median its 10-year median of 0.17. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.47. The Biotechnology industry median Debt-to-EBITDA is 1.21. Asymchem Laboratories Tianjin Co's value of 0.22 is 81.7% below this industry median. Based on the distribution chart, Asymchem Laboratories Tianjin Co ranks #75 out of 292 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Asymchem Laboratories Tianjin Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asymchem Laboratories Tianjin Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Asymchem Laboratories Tianjin Co ranks #75 out of 292 companies for Debt-to-EBITDA. This puts Asymchem Laboratories Tianjin Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.21. Asymchem Laboratories Tianjin Co's value of 0.22 is 81.7% below this benchmark. Historically, Asymchem Laboratories Tianjin Co's own Debt-to-EBITDA has ranged from 0.03 to 0.47 over the past decade. While the company's 10-year median is 0.17 vs. the industry median of 1.21, Asymchem Laboratories Tianjin Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.21, based on 292 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asymchem Laboratories Tianjin Co's current Debt-to-EBITDA of 0.22 is 81.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Asymchem Laboratories Tianjin Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asymchem Laboratories Tianjin Co's current Debt-to-EBITDA is 0.22, which is 29% above median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asymchem Laboratories Tianjin Co stock overvalued right now?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co (ASLTY) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.88, compared to a current price of $6.37 — trading 64.2% above its estimated fair value. The current Debt-to-EBITDA is 0.22, which is 29% above median its 10-year median of 0.17 and 81.7% below the Biotechnology industry median of 1.21. Asymchem Laboratories Tianjin Co's overall GF Score™ is 69/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Asymchem Laboratories Tianjin Co (ASLTY), the current Debt-to-EBITDA is 0.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asymchem Laboratories Tianjin Co (ASLTY) Overvalued in 2026?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co stock appears to be overvalued.
The current stock price of $6.37 is trading 64.2% above its estimated GF Value™ of $3.88.
GuruFocus considers Asymchem Laboratories Tianjin Co to be Significantly Overvalued.
Key valuation signals for ASLTY:
Debt-to-EBITDA: 0.22 (29% above median its 10-year median of 0.17)
GF Value™: $3.88 vs. price of $6.37 (64.2% above fair value)
Industry Position: 81.7% below the Biotechnology median (#75 of 292)
No single metric tells the full story. See the ASLTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asymchem Laboratories Tianjin Co Business Description
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focus on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
69GF Score
Get the complete analysis for ASLTY
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASLTY has been successfully added to your 
